Physiomics plc
("Physiomics") or ("the Company")
Physiomics to present the second validation of its Virtual Tumour Clinical platform at the CASyM Systems Biology Academia/Industry workshop in Lyon on April 10th
Physiomics plc (AIM: PYC), the Oxford, UK based systems biology company, is pleased to announce that it is presenting at the CASyM Academic / Industry interaction workshop taking place in Lyon (France) on April 10th 2014. Dr Hitesh Mistry will present on validation of the Virtual Tumour Clinical platform in melanoma to an audience that will comprise senior academics and large pharmaceutical company scientists.
With this new study the Company has demonstrated that Virtual Tumour Clinical can be used to make accurate predictions of clinical outcomes, using only pre-clinical PK/PD and some limited clinical PK data as a start point. The Company targeted a phase II clinical study of Docetaxel versus Docetaxel/Selumetinib in metastatic melanoma and showed that Virtual Tumour Clinical was able to accurately predict the mean change in tumour lesion diameter in both arms of the study. For the second time Virtual Tumour Clinical was able to make precise clinical predictions demonstrating that the model structure is highly relevant and useful in this context.
This study represents the validation of Virtual Tumour Clinical in melanoma and is the result of a three month collaboration with Professor Mark Middleton at the University of Oxford/The Oxford University hospitals NHS trust. This work is a part of the collaborative agreement announced on the 11th of November 2013. The study was supported by the UK's innovation agency, the Technology Strategy Board.
The presentation will take place in the "Flash presentation of innovative technological offers by SME or SME projects" session.
More information about the conference may be found at:
http://lyonbiopole.com/formulaires/Casym_2014/
Dr Mark Chadwick, CEO of Physiomics, commented:
"We are delighted to present this further validation of our flagship Virtual Tumour Clinical technology which could revolutionise how clinical dosing and scheduling regimens are chosen. Following on from our validation study in prostate cancer, these results suggest that Virtual Tumour Clinical is generally applicable to all tumour types. Predicting Clinical outcomes for particular drug regimens is of significant interest to large pharmaceutical companies and could help them to increase their drug development success rates. We believe this should make the platform extremely interesting to large pharma, the first of which we hope to sign up in the near future."
Enquiries:
Physiomics plc
Dr Mark Chadwick, CEO
+44 (0)1865 784 980
WH Ireland Limited (broker/nomad)
Katy Mitchell
+44 (0) 161 832 2174
About Physiomics plc
Physiomics (AIM:PYC) is a computational systems biology services company applying simulations of cell behaviour to drug development to reduce the high attrition rates of clinical trials. 80-90 per cent of all clinical drug candidates fail to reach the market and estimates show that an overall ten per cent improvement in success rates could reduce the cost of one drug's development by as much as $242 million, from the current estimate of around $800 million1.
Physiomics develops computational systems biology models to predict and understand cancer drug efficacy from pre-clinical research to clinical development. Physiomics has created detailed mathematical models incorporating the most important molecular events taking place during the human cell cycle and apoptosis processes. The company's SystemCell® technology enables the simulation of populations of "virtual cells". The company has also developed a "Virtual Tumour" model to simulate the effect of anti-cancer drugs on tumour growth. The models are used to optimise compound design and to design drug schedules and combination therapies.
Physiomics, based in Oxford, UK, was founded in 2001, and floated on AIM in 2004. For further information, please visit www.physiomics-plc.com
SystemCell® is a registered trademark of Physiomics plc
1Tufts Centre Impact Report 2002
About The Technology Strategy Board
The Technology Strategy Board is the UK's innovation agency. Its goal is to accelerate economic growth by stimulating and supporting business-led innovation. Sponsored by the Department for Business, Innovation and Skills (BIS), the Technology Strategy Board brings together business, research and the public sector, supporting and accelerating the development of innovative products and services to meet market needs, tackle major societal challenges and help build the future economy. For more information please visit http://www.innovateuk.org/
About the ECMC Network
Oxford Experimental Cancer Medicine Centre (ECMC) is part of a national network jointly supported by Cancer Research UK, the National Institute for Health Research in England, and the Departments of Health of Scotland, Wales and Northern Ireland. It launched in 2006, with £35M funding over five years, with a further £35M announced in 2011 for five more years to fund centres across the UK. Each ECMC brings together lab-based experts in cancer biology with cancer doctors to speed up the flow of ideas from the lab bench to the patient's bedside. Find out more at www.ecmcnetwork.org.uk
The Oxford University Hospitals NHS Trust (OUH) is one of the largest acute teaching trusts in the UK, with a national and international reputation for the excellence of its services and its role in patient care, teaching and research. The Trust supports world-leading research programmes in cardiovascular diseases, musculoskeletal disorders, neurological disorders such as Parkinson's and Alzheimer's through its designation as one of the UK's five comprehensive biomedical centres and units. It works in close partnership with the University of Oxford and is a leading centre for cancer, neurosciences, diabetes, genetics and many other fields. Research themes of particular strength are: cancer, cardiovascular science, diabetes, endocrinology & metabolism, infection and immunology, musculoskeletal science, neuroscience and reproduction and development. The Trust has been designated as a major trauma centre and is one of four UK centres for craniofacial surgery and The Trust employs 11,000 staff and consists of four hospitals: the Churchill Hospital, John Radcliffe Hospital and Nuffield Orthopaedic Centre in Oxford and the Horton General Hospital in Banbury. www.ouh.nhs.uk
Oxford University's Medical Sciences Divisionis one of the largest biomedical research centres in Europe, with over 2,500 people involved in research and more than 2,800 students. The University is rated the best in the world for medicine, and it is home to the UK's top-ranked medical school.
From the genetic and molecular basis of disease to the latest advances in neuroscience, Oxford is at the forefront of medical research. It has one of the largest clinical trial portfolios in the UK and great expertise in taking discoveries from the lab into the clinic. Partnerships with the local NHS Trusts enable patients to benefit from close links between medical research and healthcare delivery.
A great strength of Oxford medicine is its long-standing network of clinical research units in Asia and Africa, enabling world-leading research on the most pressing global health challenges such as malaria, TB, HIV/AIDS and flu. Oxford is also renowned for its large-scale studies which examine the role of factors such as smoking, alcohol and diet on cancer, heart disease and other conditions.
